Abstract
A series of different Schiff bases of isatin 1-20 was synthesized by the condensation of isatin with primary aromatic amines. It was observed that some of these compounds have the potential to inhibit acetylcholinesterase, whereas some others showed specific activity against butyrylcholinesterase, depending upon substitution on the aromatic ring. Compounds 9 and 20 showed weak acetylcholinesterase inhibitory activity having IC50 values 28.3 ± 0.26 and 159 ± 2.9 μM, respectively. Nonetheless, compounds showed a varying degree of activity against butyrylcholinesterase with IC50 values in the range of 2.8 ± 0.07-82.9 ± 2.2 μM. Compounds 5, 2, and 11 showed IC50 values 2.8 ± 0.07, 5.2 ± 0.10, and 8.1 ± 0.30 μM, respectively, Their activity was compared with standard inhibitor galanthamine IC50 = 0.5 ± 0.01 μM for acetylcholinesterase and IC50 = 8.5 ± 0.01 μM for butyrylcholinesterase, respectively. The structures of all the synthesized compounds were confirmed by spectroscopic analysis.
Keywords: Isatin, Schiff bases, Substitution effect, Butyrylcholinesterase inhibition, Galanthamine, Structure-activity relationship, Acetylcholinestrase inhibition, Butyrylcholinesterase, Gal-anthamine, AChE, senile dementia, Alzheimer's dis-ease, BChE, acetylcholine, indoles, triazoles, spiroheterocy-cle, quinolones, CHN analysis, H-NMR, EI MS, IR, UV spectroscopy, spectrometer, MeOH, Enzyme Inhibition Assay, TLC, EtOH
Letters in Drug Design & Discovery
Title: Schiff Bases of Isatin: Inhibitory Potential Towards Acetylcholinesterase and Butyrylcholinesterase
Volume: 7 Issue: 10
Author(s): Khalid Mohammed Khan, Uzma Rasool Mughal, Nida Ambreen, Nasim Hasan Rama, Farzana Naz, Shahnaz Perveen and Muhammad Iqbal Choudhary
Affiliation:
Keywords: Isatin, Schiff bases, Substitution effect, Butyrylcholinesterase inhibition, Galanthamine, Structure-activity relationship, Acetylcholinestrase inhibition, Butyrylcholinesterase, Gal-anthamine, AChE, senile dementia, Alzheimer's dis-ease, BChE, acetylcholine, indoles, triazoles, spiroheterocy-cle, quinolones, CHN analysis, H-NMR, EI MS, IR, UV spectroscopy, spectrometer, MeOH, Enzyme Inhibition Assay, TLC, EtOH
Abstract: A series of different Schiff bases of isatin 1-20 was synthesized by the condensation of isatin with primary aromatic amines. It was observed that some of these compounds have the potential to inhibit acetylcholinesterase, whereas some others showed specific activity against butyrylcholinesterase, depending upon substitution on the aromatic ring. Compounds 9 and 20 showed weak acetylcholinesterase inhibitory activity having IC50 values 28.3 ± 0.26 and 159 ± 2.9 μM, respectively. Nonetheless, compounds showed a varying degree of activity against butyrylcholinesterase with IC50 values in the range of 2.8 ± 0.07-82.9 ± 2.2 μM. Compounds 5, 2, and 11 showed IC50 values 2.8 ± 0.07, 5.2 ± 0.10, and 8.1 ± 0.30 μM, respectively, Their activity was compared with standard inhibitor galanthamine IC50 = 0.5 ± 0.01 μM for acetylcholinesterase and IC50 = 8.5 ± 0.01 μM for butyrylcholinesterase, respectively. The structures of all the synthesized compounds were confirmed by spectroscopic analysis.
Export Options
About this article
Cite this article as:
Mohammed Khan Khalid, Rasool Mughal Uzma, Ambreen Nida, Hasan Rama Nasim, Naz Farzana, Perveen Shahnaz and Iqbal Choudhary Muhammad, Schiff Bases of Isatin: Inhibitory Potential Towards Acetylcholinesterase and Butyrylcholinesterase, Letters in Drug Design & Discovery 2010; 7 (10) . https://dx.doi.org/10.2174/1570180811007010716
DOI https://dx.doi.org/10.2174/1570180811007010716 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Comparison of Clinical Outcomes Between Genders Following Antihypertensive Therapy: A Meta-Analysis
Current Medicinal Chemistry Experimental and Clinical Application of Plasmid DNA in the Field of Central Nervous Diseases
Current Gene Therapy The Role of the Thrombospondins in Healing Myocardial Infarcts
Cardiovascular & Hematological Agents in Medicinal Chemistry Calcium Antagonists: A Ready Prescription for Treating Infectious Diseases?
Current Topics in Medicinal Chemistry Graphical Abstracts:
Current Hypertension Reviews An Angiotensin Converting Enzyme Inhibitor Suppresses Contrast Media Induced Renal Dysfunction in a Murine Model of Subtotal Nephrectomy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Role of Asymmetric Dimethylarginine (ADMA) in Diabetic Vascular Complications
Current Pharmaceutical Design The Therapeutic Applications of Exosomes in Different Types of Diseases: A Review
Current Molecular Medicine The Incidence of Adverse Drug Reactions in Patients Treated with Statins in the Emirates: A Retrospective Cohort Study
Current Vascular Pharmacology Selective Estrogen Receptor Modulators and Aromatase Inhibitors for Breast Cancer Chemoprevention
Current Drug Targets Nonalcoholic Fatty Liver Disease and Cardiovascular Disease
Current Pharmaceutical Design Optimization of Important Early ADME(T) Parameters of NADPH Oxidase-4 Inhibitor Molecules
Medicinal Chemistry Relations of Magnesium Intake with Metabolic Risk Factors and Risks of Type 2 Diabetes, Hypertension, and Cardiovascular Disease: A Critical Appraisal
Current Nutrition & Food Science Vasopressin Receptor Antagonists in Heart Failure
Recent Patents on Cardiovascular Drug Discovery Childhood and Adulthood Rural Residence Increases the Risk of Dementia: NEDICES Study
Current Alzheimer Research Hemoglobin Encapsulated Poly(Ethylene Glycol) Surface Conjugated Vesicles Attenuate Vasoactivity of Cell-Free Hemoglobin
Current Drug Discovery Technologies <i>In silico</i> Approach for Exploring the Role of AT1R Polymorphism on its Function, Structure and Drug Interactions
Current Computer-Aided Drug Design Manoyl-Oxide Biotransformations with Filamentous Fungi
Current Organic Chemistry Emerging Targeted Therapies in Metastatic Renal Cell Carcinoma
Current Clinical Pharmacology Role of Reactive Oxygen Species in Tumor Necrosis Factor-alpha Induced Endothelial Dysfunction
Current Hypertension Reviews